Lu Yan, Li De-Hong, Xu Ji-Mei, Zhou Sheng
Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, China.
Department of General Surgery, Gansu Provincial Hospital, Lanzhou, China.
Front Pharmacol. 2024 Sep 6;15:1451445. doi: 10.3389/fphar.2024.1451445. eCollection 2024.
Atherosclerosis (AS) is a major pathological basis of coronary heart disease. However, the currently available medications are unable to effectively reduce the incidence of cardiovascular events in the majority of patients with AS. Therefore, naringin has been attracting considerable attention owing to its anti-AS effects. Naringin can inhibit the growth, proliferation, invasion, and migration of vascular smooth muscle cells, ameliorate endothelial cell inflammation and apoptosis, lower blood pressure, halt the cell cycle at the G1 phase, and impede growth via its antioxidant and free radical scavenging effects. These activities suggest the potential anti-AS effects of naringin. In this review article, we comprehensively summarized the latest findings on the anti-AS effects of naringin and their underlying mechanisms, providing a crucial reference for future research on the anti-AS potential of this agent.
动脉粥样硬化(AS)是冠心病的主要病理基础。然而,目前可用的药物无法有效降低大多数AS患者心血管事件的发生率。因此,柚皮苷因其抗AS作用而备受关注。柚皮苷可抑制血管平滑肌细胞的生长、增殖、侵袭和迁移,改善内皮细胞炎症和凋亡,降低血压,使细胞周期停滞在G1期,并通过其抗氧化和清除自由基的作用阻碍生长。这些作用表明柚皮苷具有潜在的抗AS作用。在这篇综述文章中,我们全面总结了柚皮苷抗AS作用及其潜在机制的最新研究结果,为该药物抗AS潜力的未来研究提供了重要参考。